News | Cardiovascular Clinical Studies | July 31, 2023

Study Confirms Ultromics' AI Can Improve HFpEF Detection Using a Single Echocardiogram View

AI demonstrated high accuracy, reduced non-diagnostic outputs, and identified HFpEF patients with worse outcomes

AI demonstrated high accuracy, reduced non-diagnostic outputs, and identified HFpEF patients with worse outcomes.

The study found AI could improve the diagnosis, management, and outcomes of HFpEF; a deadly form of heart failure that often goes undetected. (PRNewsfoto/Ultromics) 


July 31, 2023 — Applying AI to a single apical four chamber (A4C) view echocardiogram provides accurate information to detect heart failure with preserved ejection fraction (HFpEF), according to research published in JACC Advances

The study, presented at the American Society of Echocardiography Annual Scientific Session, demonstrates the platform could improve the diagnosis, management, and outcomes of a condition that currently often goes undetected, or requires additional invasive procedures to confirm. 

Ultromics' EchoGo Heart Failure accurately detected HFpEF and provided fewer non-diagnostic outputs than current clinical scores, using just the routinely acquired A4C view from a transthoracic echocardiographic (TTE). The novel technology, which was recently granted clearance and Breakthrough Device designation by the FDA, identifies radiomic signatures of disease that are not evident to the human eye. 

Senior study author, Patricia A. Pellikka, M.D, Vice Chair in the Department of Cardiovascular Medicine at Mayo Clinic, said: "HFpEF can be difficult to detect, but left undetected and untreated, can result in hospitalization and mortality. As the first AI platform cleared to detect the condition, EchoGo Heart Failure can fill a significant unmet need." 

"With more than 32 million people living with HFpEF, and the incidence increasing, clinicians will benefit from having another means to recognize this disease." 

Based on the AI findings, patients could potentially be started on medications to treat their condition earlier than if they had to wait for an invasive diagnostic assessment of the disease. 

The AI model was trained and developed on 6,756 patients who underwent a comprehensive TTE at Mayo Clinic in Rochester, Minnesota, between January 2009 to December 2020. It was then independently tested in geographically distinct areas within Mayo Clinic enterprise System sites across the United States, on a dataset that included 1,284 patients.  

EchoGo Heart Failure demonstrated high sensitivity and specificity, detecting 87.8% of patients who had HFpEF, and 81.9% of patients that did not.1 These results exceed what is usually observed in routine clinical practice. 

It was also able to assign a correct diagnosis to 74% of patients who had returned non-diagnostic results on the commonly used HFA-PEFF and H2FPEF clinical scores.1 This improvement could translate to more patients receiving accurate and timely diagnoses and management. 

During the follow-up period of up to 5 years, 444 patients died, highlighting the poor outcomes associated with HFpEF. The AI model was able to identify patients with worse survival, demonstrating its capacity to meaningfully improve patient outcomes. 

Ross Upton, PhD, CEO and Founder of Ultromics, said: "Our research demonstrates the tremendous potential of AI in revolutionizing the detection of HFpEF. EchoGo Heart Failure's exceptional discrimination capabilities combined with its ability to identify patients with higher mortality risks holds great promise for improving patient outcomes and enabling faster access to treatment." 

"In a large number of cases, diagnostic data are often missing or discordant, making HFpEF detection challenging. AI can enhance echocardiography capabilities to help practices overcome the cumbersome intricacy of diastolic assessment. It is particularly useful for clinical centers that lack the time, resources, or expertise to perform comprehensive, diagnostic-quality, assessments." 

By streamlining the screening process for this complex clinical syndrome, EchoGo Heart Failure paves the way for more patients to receive the care they need sooner, potentially preventing more severe outcomes, and reducing HFpEF's significant burden on patients and healthcare. 

Ultromics remains committed to advancing AI technology to transform cardiovascular healthcare. The groundbreaking findings from this study underscore the company's dedication to empowering healthcare professionals with tools that overcome existing bottlenecks and enhance patient care. 

For more information: https://www.ultromics.com/ 

 

Related Content: 

CMS Establishes HCPCS code for Ultromics EchoGo Heart Failure 

Ultromics Granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis Detection 

Ultromics Receives FDA Clearance for AI-based Platform for Echocardiography 


Related Content

News | FDA

February 6, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home February 06, 2024
Home
News | FDA

February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is ...

Home February 02, 2024
Home
News | FDA

January 31, 2024 — As part of efforts to continuously improve medical solutions for patients with complex vascular ...

Home January 31, 2024
Home
News | FDA

January 31, 2024 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home January 31, 2024
Home
News | FDA

November 20, 2023 — A groundbreaking advancement in the treatment of patients with uncontrolled hypertension (HTN) has ...

Home November 20, 2023
Home
News | FDA

November 17, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home November 17, 2023
Home
News | FDA

November 8, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. has announced that the U ...

Home November 08, 2023
Home
News | FDA

November 7, 2023 — The U.S. Food and Drug Administration (FDA) announced that Teleflex, and its subsidiary Arrow ...

Home November 07, 2023
Home
News | FDA

October 4, 2023 — Anumana, Inc., a leading AI-driven health technology and nference portfolio company working in ...

Home October 04, 2023
Home
Subscribe Now